CERo Therapeutics (CEROW) Competitors $0.01 0.00 (-0.75%) As of 10/1/2025 03:22 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock CEROW vs. ATNFW, SXTPW, DRTSW, APLMW, BCTXW, CDIOW, CELUW, CINGW, CLNNW, and COEPWShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), Cingulate (CINGW), Clene (CLNNW), and Coeptis Therapeutics (COEPW). These companies are all part of the "biotechnology" industry. CERo Therapeutics vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Celularity Cingulate Clene Coeptis Therapeutics CERo Therapeutics (NASDAQ:CEROW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability. Does the media refer more to CEROW or ATNFW? In the previous week, CERo Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for 180 Life Sciences. CERo Therapeutics' average media sentiment score of 1.00 beat 180 Life Sciences' score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the media. Company Overall Sentiment CERo Therapeutics Positive 180 Life Sciences Neutral Is CEROW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets CERo TherapeuticsN/A N/A N/A 180 Life Sciences N/A N/A N/A Which has better valuation and earnings, CEROW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCERo TherapeuticsN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A SummaryCERo Therapeutics beats 180 Life Sciences on 2 of the 2 factors compared between the two stocks. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CEROW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CEROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CEROW vs. The Competition Export to ExcelMetricCERo TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$232.84M$6.03B$10.57BDividend YieldN/A3.80%5.92%4.70%P/E RatioN/A31.6276.4726.50Price / SalesN/A5,496.91583.32128.74Price / CashN/A13.1938.1961.33Price / BookN/A108.2812.546.48Net IncomeN/A-$90.99M$3.30B$277.02M7 Day PerformanceN/A2.03%28,086.97%1.84%1 Month PerformanceN/A6.36%30,478.95%8.29%1 Year PerformanceN/A563.41%35,729.69%36.66% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROWCERo TherapeuticsN/A$0.01-0.8%N/A+116.4%$0.00N/A0.008Positive NewsShort Interest ↓ATNFW180 Life SciencesN/A$0.08-2.3%N/A+720.8%$0.00N/A0.007SXTPW60 Degrees PharmaceuticalsN/A$0.04+1.1%N/A-38.6%$0.00$641.41K0.002Positive NewsShort Interest ↓Gap UpDRTSWAlpha Tau MedicalN/A$0.33-4.4%N/A+81.0%$0.00N/A0.0080Positive NewsShort Interest ↓APLMWApollomicsN/A$0.02+14.4%N/A+109.9%$0.00N/A0.0059Positive NewsShort Interest ↑Gap DownHigh Trading VolumeBCTXWBriaCell TherapeuticsN/A$0.04+43.4%N/A-87.2%$0.00N/A0.008Short Interest ↑Gap UpCDIOWCardio DiagnosticsN/A$0.02-20.0%N/A-34.9%$0.00$19.51K0.007Positive NewsHigh Trading VolumeCELUWCelularityN/A$0.05+24.8%N/A+272.0%$0.00$44.59M0.00220Positive NewsShort Interest ↓CINGWCingulateN/A$0.05+10.2%N/A+2.6%$0.00N/A0.0020Positive NewsShort Interest ↑Gap UpCLNNWCleneN/A$0.03+0.3%N/AN/A$0.00$286K0.00100Positive NewsGap DownCOEPWCoeptis TherapeuticsN/A$0.02-18.4%N/A+33.9%$0.00$263.56K0.004Positive NewsShort Interest ↑Gap Down Related Companies and Tools Related Companies ATNFW Competitors SXTPW Competitors DRTSW Competitors APLMW Competitors BCTXW Competitors CDIOW Competitors CELUW Competitors CINGW Competitors CLNNW Competitors COEPW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CEROW) was last updated on 10/2/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredThis Biotech has a clinical approach that intrigues investorsThis biotech is gearing up for Phase 2 trials with a strategy to unlock multiple approvals from one study. ...i2i Marketing Group, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAmerica’s Lost StocksPorter Stansberry says the real fortunes aren’t in Tesla, Amazon, or AI — but in a handful of overlooked “lost...Porter & Company | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
